Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers - Nasser, Azmi F.; Heidbreder, Christian; Liu, Yongzhen; Fudala, Paul J. (Clinical pharmacokinetics, 2015)
Keywords: Adult; Buprenorphine, Naloxone Drug Combination - administration & dosage; Buprenorphine, Naloxone Drug Combination - blood; Buprenorphine, Naloxone Drug Combination - pharmacokinetics; Case-Control Studies; Female; Hepatitis C - blood; Hepatitis C - drug therapy; Hepatitis C - metabolism; Hepatitis C - virology; Humans; Internal Medicine; Liver Diseases - blood; Liver Diseases - drug therapy; Liver Diseases - metabolism; Liver Diseases - virology; Male; Medicine; Medicine & Public Health; Middle Aged; Opioid-Related Disorders - blood; Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - metabolism; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Young Adult; Naloxone; Opioid Dependence; Buprenorphine; Hepatic Impairment; Plasma Protein Binding